Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium ( 177 Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback